Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the …
X Wang, D Goldstein, PJ Crowe… - OncoTargets and …, 2016 - Taylor & Francis
Tyrosine kinase inhibitors (TKIs) against human epidermal growth factor receptor
(EGFR/HER) family have been introduced into the clinic to treat cancers, particularly non …
(EGFR/HER) family have been introduced into the clinic to treat cancers, particularly non …
[HTML][HTML] Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line
I Sullivan, D Planchard - Frontiers in medicine, 2017 - frontiersin.org
Tyrosine kinase inhibitors (TKIs) against the human epidermal growth factor receptor
(EGFR) are now standard treatment in the clinic for patients with advanced EGFR mutant …
(EGFR) are now standard treatment in the clinic for patients with advanced EGFR mutant …
[HTML][HTML] Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer
K Asami, S Atagi - World journal of clinical oncology, 2014 - ncbi.nlm.nih.gov
First-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs),
including gefitinib and erlotinib, have proven to be highly effective agents for advanced non …
including gefitinib and erlotinib, have proven to be highly effective agents for advanced non …
Treatment options for EGFR T790M-negative EGFR tyrosine kinase inhibitor-resistant non-small cell lung cancer
The introduction of first-and second-generation EGFR-tyrosine kinase inhibitors
(TKIs)(gefitinib, erlotinib and afatinib) for the treatment of advanced EGFR-mutant non-small …
(TKIs)(gefitinib, erlotinib and afatinib) for the treatment of advanced EGFR-mutant non-small …
Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): the road to a success, paved with failures
DH Lee - Pharmacology & therapeutics, 2017 - Elsevier
The discovery of epidermal growth factor receptor (EGFR) activating mutations in non-small
cell lung cancer (NSCLC) and the success story of EGFR tyrosine kinases inhibitors (TKIs) …
cell lung cancer (NSCLC) and the success story of EGFR tyrosine kinases inhibitors (TKIs) …
Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy
BC Liao, CC Lin, JH Lee, JCH Yang - Lung Cancer, 2017 - Elsevier
The first-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs),
gefitinib and erlotinib, and the second-generation EGFR-TKI, afatinib, have all been …
gefitinib and erlotinib, and the second-generation EGFR-TKI, afatinib, have all been …
The role of EGFR tyrosine kinase inhibitors in the first-line treatment of advanced non small cell lung cancer patients harboring EGFR mutation
A Sgambato, F Casaluce, P Maione… - Current medicinal …, 2012 - ingentaconnect.com
Lung cancer continues to be the leading cause of cancer death worldwide. Among lung
cancers, 80% are classified as nonsmall-cell lung cancer (NSCLC) and are mostly …
cancers, 80% are classified as nonsmall-cell lung cancer (NSCLC) and are mostly …
[HTML][HTML] Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors
X Du, B Yang, Q An, YG Assaraf, X Cao, J Xia - The Innovation, 2021 - cell.com
The discovery that mutations in the EGFR gene are detected in up to 50% of lung
adenocarcinoma patients, along with the development of highly efficacious epidermal …
adenocarcinoma patients, along with the development of highly efficacious epidermal …
[HTML][HTML] EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer
X Nan, C Xie, X Yu, J Liu - Oncotarget, 2017 - ncbi.nlm.nih.gov
After the discovery of activating mutations in EGFR, EGFR tyrosine kinase inhibitors (TKIs)
have been introduced into the first-line treatment of non-small-cell lung cancer (NSCLC). A …
have been introduced into the first-line treatment of non-small-cell lung cancer (NSCLC). A …
[HTML][HTML] Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: Focus on afatinib
The development of first-, second-, and third-generation epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of patients with non …
(EGFR) tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of patients with non …